Clinical trialNCT01487863CompletedPhase 2Interventional

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

SponsorDendreonEnrollment69Castration-resistant Prostate CancerHormone Refractory Prostate CancerProstate Cancer Metastatic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters), and to assess the safety and efficacy of sipuleucel-T with concurrent or sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Robert Israel, MD
Valeant Pharmaceuticals North America LLC
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moores Ucsd Cancer Center
La Jolla, California, United States
Ucsd Medical Center - la Jolla
La Jolla, California, United States
Cancer Center Oncology Medical Group
La Mesa, California, United States
Medical Oncology Associates - Sd
San Diego, California, United States
Sharp Rees-Stealy
San Diego, California, United States
Ucsd Medical Center - Hillcrest
San Diego, California, United States
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
the Urology Center of Colorado
Denver, Colorado, United States
Georgetown University Medical Center - Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Indiana University
Indianapolis, Indiana, United States
Mid Atlantic Urology Associates, Mid Atlantic Clinical Research
Greenbelt, Maryland, United States
Gu Research Center, Llc
Omaha, Nebraska, United States
Nyu Clinical Cancer Center, Nyu Langone Medical Center
New York, New York, United States
the Mount Sinai Medical Center
New York, New York, United States
Associated Medical Professionals of Ny, Pllc
Oneida, New York, United States
Associated Medical Professionals of New York, Pllc
Syracuse, New York, United States
Providence Cancer Center Oncology and Hematology Care
Portland, Oregon, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Urology Associates, P.C.
Nashville, Tennessee, United States
Urology of Virginia
Virginia Beach, Virginia, United States
Virginia Mason Medical Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abiraterone →Sipuleucel-T →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2011
Primary completion: 31 May 2016
Completion: 30 Jun 2016
Last update posted: 19 Mar 2019
Registered enrollment: 69
Registry id: NCT01487863

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.